Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Lymphokines – e.g. – interferons – interlukins – etc.
Reexamination Certificate
2006-12-05
2006-12-05
Saoud, Christine J. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Lymphokines, e.g., interferons, interlukins, etc.
C530S350000, C435S069500, C435S335000, C435S007100
Reexamination Certificate
active
07144987
ABSTRACT:
The invention relates to novel proteins with TNF-receptor antagonist activity and nucleic acids encoding these proteins. The invention further relates to TNF-receptor proteins with reduced immunogenicity and the use of these novel proteins in the treatment of TNF related disorders.
REFERENCES:
patent: 5344915 (1994-09-01), LeMaire et al.
patent: 5395760 (1995-03-01), Smith et al.
patent: 5478925 (1995-12-01), Wallach et al.
patent: 5512544 (1996-04-01), Wallach et al.
patent: 5605690 (1997-02-01), Jacobs et al.
patent: 5610279 (1997-03-01), Brockhaus et al.
patent: 5695953 (1997-12-01), Wallach et al.
patent: 5712155 (1998-01-01), Smith et al.
patent: 5808029 (1998-09-01), Brockhaus et al.
patent: 5811261 (1998-09-01), Wallach et al.
patent: 5925548 (1999-07-01), Beutler et al.
patent: 5945397 (1999-08-01), Smith et al.
patent: 5981701 (1999-11-01), Wallach et al.
patent: 6271346 (2001-08-01), Hauptmann et al.
patent: 6433158 (2002-08-01), Pettit
patent: 0 433 900 (1991-06-01), None
patent: 0 526 905 (1993-02-01), None
patent: 03-133382 (1991-06-01), None
patent: 03-163099 (1991-07-01), None
patent: 10-191986 (1998-07-01), None
patent: WO 92/07076 (1992-04-01), None
patent: WO 92/13095 (1992-08-01), None
Ngo et al., 1994, The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495.
Wells, Aditivity of Mutational Effects in Proteins, 1990, Biochemistry, vol. 26, No. 37, pp. 8509-8517.
Adam-Klages S, et al, “FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase.” Cell. 1996 Sep. 20:86(6):937-47.
Adolf GR, and Fruhbais B, “Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity.” Cytokine. May;4(3):180-4 (1992).
Banner DW, et al., “Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: Implications for TNF receptor activation.” Cell. May 7;73(3):431-45 (1993).
Beutler B, et al., “Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.” Nature. Aug. 8-14;316(6028):552-4 (1985).
Brakebusch C, et al., “Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor aboloshes signalling, but not induced shedding of the receptor,” EMBO J. Mar.;11(3):943-50 (1992).
Carswell EA, et al., “An endotoxin-induced serum factor that causes necrosis of tumors.” Proc. Natl Acad Sci U S A. Sep.;72(9):3666-70 (1975).
Christen U, et al, “Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatold arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities,” Hum Immunol. Sep.;60(9):774-90 (1999).
Corcoran AE, et al., “Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats.” Eur J Biochem. Aug. 1;223(3):831-40 (1994).
Eck MJ, et al., “The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution.” J Biol Chem. Feb. 5;267(4):2119-22 (1992).
Edwards CK 3rd. “PEGylated recombinant human soluble tumour necrosis factor receptor type l (r-Hu-sTNF-Rl): novel high affinity TNF receptor designed for chronic inflammatory diseases.” Ann Rheum Dis. Nov.;58 Suppl 1:l73-81 (1999).
Engelmann H, et al., “Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors.” J Biol Chem, Jan. 25;265(3):1531-6 (1990).
Espevik T , and Nissen-Meyer J. “A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes,” J Immunol Methods. Dec. 4;95(1):99-105 (1986).
Grell M, “The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.” Cell. Dec. 1;83(5):793-802 (1995).
Haak-Frendscho M, et al., “Inhibition of TNF by a TNF receptor immunoadhesin. Comparison to an anti-TNF monoclonal antibody.” J Immunol. Feb. 1;152(3):1347-53 (1994).
Hakoshima T, and Tomita K. “Crystallization and preliminary X-ray investigation reveals that tumor necrosis factor is a compact trimer furnished with 3-fold symmetry.” J Mol Biol. May 20;201(2):455-7 (1988).
Headon DJ, and Overbeek PA. “Involvement of a novel Tnf receptor homologue in hair follicle induction.” Nat Genet. Aug.;22(4):370-4. (1999).
Jones EY, et al., “Structure of tumour necrosis factor.” Nature. Mar. 16;338(6212):225-8 (1989).
Kim H, et al., “Receptor activator of NF-KB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase.” FEBS Lett. Dec. 7;443:297-302 (1999).
Kim I, “Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3.” FEBS Lett. Jan. 29;443(3):353-6 (1999).
Loetscher H, et al., “Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor.” Cell. Apr. 20;61(2):351-9 (1990).
Loetscher H, et al., “Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells.” J Biol Chem. Nov. 25;265(33):20131-8 (1990).
Loetscher H, et al., “Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity.” J Biol Chem. Sep. 25;266(27):18324-9 (1991).
Moreland LW. “Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis.” Cleve Clin J Med. Jun.;66(6):367-74 (1999).
Naismith JH, et al., “Crystallographic Evidence for Dimerization of Unliganded Tumor Necrosis Factor Receptor.” J Biol Chem. Jun. 2;270(2):13303-13307 (1995).
Naismith JH, and Sprang SR. “Modularity in the TNF-receptor family,” Trends Biochem Sci. Feb.;23(2):74-9 (1998).
Naismith JH, et al., “Structures of the extracellular domain of the type l tumor necrosis factor receptor.” Structure. Nov. 15;4(11):1241-62 (1996).
Old LJ. “Tumor necrosis factor (TNF).” Science. Nov. 8;230(4726):630-2 (1985).
Olsson I, et al., “Isolation and characterization of a tumor necrosis factor binding protein from urine.” Eur J Haematol. Mar.;42(3):270-5 (1989).
Paquot N, “No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients.” J Clin Endocrinol Metab. Mar.;85(3):1316-9 (2000).
Park YC, “Structural basis for self-association and receptor recognition of human TRAF2.” Nature. Apr. 8;398(6727):533-8 (1999).
Rodseth LE, et al., “Two crystal forms of the extracellular domain of type l tumor necrosis factor receptor.” J Mol Biol. Jun. 3;239(2):332-5 (1994).
Scallon BJ, et al., “Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins.” Cytokine. Nov.;7(8):759-70 (1995).
Schall TJ, et al., “Molecular cloning and expression of a receptor for human tumor necrosis factor.” Cell. Apr. 20;61(2):361-70 (1990).
Seckinger P, et al., “Tumor necrosis factor inhibitor: purification, NH2-terminal amino acid sequence and evidence for anti-inflammatory and immunomodulatory activities.” Eur J Immunol. May;20(5):1167-74 (1990).
Smith CA, et al., “A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins.” Science. May 25;248(4958):1019-23 (1990).
Takasaki W, “Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor.” Nat Biotechnol. Nov.;15(12):1266-70 (1997).
Tartaglia LA, and Goeddel DV. “Tumor necrosis factor receptor signaling. A dominant negative mutation suppresses the activation of the 55-kDa tumor necrosis factor re
Chirino Arthur J.
Luo Peizhi
McDonnell Peter Colon
Muchhal Umesh
Tansey Malu Lourdes
Dorsey & Whitney
Saoud Christine J.
Seharaseyon Jegatheesan
Silva Robin M.
Worrall Timothy A.
LandOfFree
Protein based tumor necrosis factor-receptor variants for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protein based tumor necrosis factor-receptor variants for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein based tumor necrosis factor-receptor variants for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3692353